- Home
- VIGL vs ZENV Comparison
VIGL vs ZENV Comparison
Compare VIGL & ZENV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ZENV
- Stock Information
- Founded
- VIGL 2020
- ZENV 2005
- Country
- VIGL United States
- ZENV Brazil
- Employees
- VIGL N/A
- ZENV N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ZENV Computer Software: Prepackaged Software
- Sector
- VIGL Health Care
- ZENV Technology
- Exchange
- VIGL Nasdaq
- ZENV Nasdaq
- Market Cap
- VIGL 125.3M
- ZENV 121.8M
- IPO Year
- VIGL 2022
- ZENV 2021
- Fundamental
- Price
- VIGL $3.44
- ZENV $1.47
- Analyst Decision
- VIGL Buy
- ZENV
- Analyst Count
- VIGL 5
- ZENV 0
- Target Price
- VIGL $16.60
- ZENV N/A
- AVG Volume (30 Days)
- VIGL 94.8K
- ZENV 19.7K
- Earning Date
- VIGL 11-05-2024
- ZENV 11-14-2024
- Dividend Yield
- VIGL N/A
- ZENV N/A
- EPS Growth
- VIGL N/A
- ZENV N/A
- EPS
- VIGL N/A
- ZENV N/A
- Revenue
- VIGL N/A
- ZENV $158,405,865.00
- Revenue This Year
- VIGL N/A
- ZENV $20.81
- Revenue Next Year
- VIGL N/A
- ZENV $10.70
- P/E Ratio
- VIGL N/A
- ZENV N/A
- Revenue Growth
- VIGL N/A
- ZENV 20.93
- 52 Week Low
- VIGL $2.47
- ZENV $0.80
- 52 Week High
- VIGL $9.24
- ZENV $3.88
- Technical
- Relative Strength Index (RSI)
- VIGL 50.19
- ZENV 41.24
- Support Level
- VIGL $3.20
- ZENV $1.45
- Resistance Level
- VIGL $3.48
- ZENV $1.54
- Average True Range (ATR)
- VIGL 0.18
- ZENV 0.07
- MACD
- VIGL 0.02
- ZENV 0.01
- Stochastic Oscillator
- VIGL 46.58
- ZENV 34.21
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.